15.21 USD
-0.01 (-0.07%)
At close: Feb 3, 2026
15.25 USD
+0.04 (+0.26%)
After Hours: 2/3/2026, 8:00:44 PM
AUPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make AUPH suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
- In the past year AUPH was profitable.
- In the past year AUPH had a positive cash flow from operations.
- In the past 5 years AUPH reported 4 times negative net income.
- In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 14.76%, AUPH belongs to the best of the industry, outperforming 95.42% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 21.28%, AUPH belongs to the top of the industry, outperforming 96.56% of the companies in the same industry.
- AUPH's Return On Invested Capital of 14.89% is amongst the best of the industry. AUPH outperforms 95.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROIC | 14.89% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of AUPH (29.28%) is better than 95.61% of its industry peers.
- AUPH's Operating Margin of 32.73% is amongst the best of the industry. AUPH outperforms 96.95% of its industry peers.
- AUPH's Gross Margin of 88.93% is amongst the best of the industry. AUPH outperforms 91.03% of its industry peers.
- In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AUPH has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, AUPH has less shares outstanding
- Compared to 5 years ago, AUPH has more shares outstanding
- AUPH has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 7.03 indicates that AUPH is not in any danger for bankruptcy at the moment.
- AUPH's Altman-Z score of 7.03 is fine compared to the rest of the industry. AUPH outperforms 77.10% of its industry peers.
- AUPH has a debt to FCF ratio of 0.60. This is a very positive value and a sign of high solvency as it would only need 0.60 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.60, AUPH belongs to the best of the industry, outperforming 94.85% of the companies in the same industry.
- A Debt/Equity ratio of 0.15 indicates that AUPH is not too dependend on debt financing.
- AUPH has a worse Debt to Equity ratio (0.15) than 63.74% of its industry peers.
- Even though the debt/equity ratio score it not favorable for AUPH, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 7.03 |
ROIC/WACC1.89
WACC7.87%
2.3 Liquidity
- A Current Ratio of 5.76 indicates that AUPH has no problem at all paying its short term obligations.
- AUPH has a Current ratio of 5.76. This is comparable to the rest of the industry: AUPH outperforms 59.92% of its industry peers.
- AUPH has a Quick Ratio of 5.17. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
- AUPH has a Quick ratio (5.17) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 609.09% over the past year.
- The Revenue has grown by 20.62% in the past year. This is a very strong growth!
- The Revenue has been growing by 279.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
3.2 Future
- AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.13% yearly.
- The Revenue is expected to grow by 14.71% on average over the next years. This is quite good.
EPS Next Y772.67%
EPS Next 2Y225.53%
EPS Next 3Y129.75%
EPS Next 5Y70.13%
Revenue Next Year19.09%
Revenue Next 2Y17.76%
Revenue Next 3Y17%
Revenue Next 5Y14.71%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 27.16 indicates a quite expensive valuation of AUPH.
- AUPH's Price/Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 93.51% of the companies in the same industry.
- AUPH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.18.
- Based on the Price/Forward Earnings ratio of 15.95, the valuation of AUPH can be described as correct.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 95.61% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.51, AUPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.16 | ||
| Fwd PE | 15.95 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 95.42% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, AUPH is valued cheaper than 96.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.73 | ||
| EV/EBITDA | 13.59 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as AUPH's earnings are expected to grow with 129.75% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y225.53%
EPS Next 3Y129.75%
5. Dividend
5.1 Amount
- No dividends for AUPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.21
-0.01 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners50.68%
Inst Owner Change-2%
Ins Owners1.92%
Ins Owner Change1.34%
Market Cap2.01B
Revenue(TTM)265.81M
Net Income(TTM)77.84M
Analysts78.46
Price Target17.05 (12.1%)
Short Float %7.15%
Short Ratio7.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.94%
Min EPS beat(2)6.95%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)66.5%
Min EPS beat(4)6.95%
Max EPS beat(4)161.28%
EPS beat(8)7
Avg EPS beat(8)112.72%
EPS beat(12)11
Avg EPS beat(12)88.48%
EPS beat(16)14
Avg EPS beat(16)70.43%
Revenue beat(2)2
Avg Revenue beat(2)7.29%
Min Revenue beat(2)6.84%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)3.01%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)7.75%
Revenue beat(8)5
Avg Revenue beat(8)4.09%
Revenue beat(12)9
Avg Revenue beat(12)8.29%
Revenue beat(16)13
Avg Revenue beat(16)10.25%
PT rev (1m)0%
PT rev (3m)42.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.31%
EPS NY rev (1m)0%
EPS NY rev (3m)18.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.16 | ||
| Fwd PE | 15.95 | ||
| P/S | 7.54 | ||
| P/FCF | 16.73 | ||
| P/OCF | 16.7 | ||
| P/B | 5.48 | ||
| P/tB | 5.54 | ||
| EV/EBITDA | 13.59 |
EPS(TTM)0.56
EY3.68%
EPS(NY)0.95
Fwd EY6.27%
FCF(TTM)0.91
FCFY5.98%
OCF(TTM)0.91
OCFY5.99%
SpS2.02
BVpS2.77
TBVpS2.74
PEG (NY)0.04
PEG (5Y)N/A
Graham Number5.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROCE | 19.28% | ||
| ROIC | 14.89% | ||
| ROICexc | 67.33% | ||
| ROICexgc | 70.07% | ||
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% | ||
| FCFM | 45.1% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score9
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.52 | ||
| Cap/Depr | 1.21% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.83% | ||
| Profit Quality | 154% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 7.03 |
F-Score9
WACC7.87%
ROIC/WACC1.89
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
EPS Next Y772.67%
EPS Next 2Y225.53%
EPS Next 3Y129.75%
EPS Next 5Y70.13%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
Revenue Next Year19.09%
Revenue Next 2Y17.76%
Revenue Next 3Y17%
Revenue Next 5Y14.71%
EBIT growth 1Y448.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9822.78%
EBIT Next 3Y402.81%
EBIT Next 5YN/A
FCF growth 1Y414.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.82%
OCF growth 3YN/A
OCF growth 5YN/A
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to AUPH.
What is the valuation status of AURINIA PHARMACEUTICALS INC (AUPH) stock?
ChartMill assigns a valuation rating of 7 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Undervalued.
Can you provide the profitability details for AURINIA PHARMACEUTICALS INC?
AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for AUPH stock?
The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 27.16 and the Price/Book (PB) ratio is 5.48.
Can you provide the expected EPS growth for AUPH stock?
The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 772.67% in the next year.